임상 한눈에 보기

• 18건의 ClinicalTrials.gov 임상 기록
• Phase·Status 요약은 enrollment 상위 표본 기준입니다
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 3 · Phase 1, Phase 2 · Phase 2 · Phase 1
• Status: Completed · Unknown status · Active, not recruiting
• 주요 endpoint: Overall Response Rate (ORR) · Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide · Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR · PR or SD more than 24 weeks) following RECIST v1.1 criteria · Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria
• 등록된 결과: ORR 33.3%
• 핵심: This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the …

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.